Search | Clinical Trials Finder

Conditions: Coronary Artery Disease, Cerebral Vascular Disease, Peripheral Artery Disease, Renal Insufficiency, Diabetes, COPD, Hypertension, Active Smoker, Cancer, CHF, Prior DVT/PE
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Pregnancy Complications, Obesity, Pre-Eclampsia, Gestational Diabetes
Interventions: Resistance exercise, Aerobic Exercise, Rest; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Kidney Disease and Hypertension
Interventions: Baxdrostat/dapagliflozin, Placebo/dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 133
States / cities: Fairhope, Alabama • Surprise, Arizona • Tucson, Arizona + 117 more

Conditions: ESRD, Extracellular Fluid Alteration, Hypertension
Interventions: Intradialytic Blood Pressure Slope Based Ultrafiltration; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions: Renal Denervation (Symplicity Spyral™); Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 76
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 67 more

Conditions: Hypertension in Pregnancy, Preeclampsia
Interventions: Nifedipine, Labetalol; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Chronic Kidney Diseases
Interventions: Dietary education program; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Pre-Eclampsia, Pregnancy Related
Interventions: nicotinamide; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Mild Autonomous Cortisol Secretion (MACS)
Interventions: Osilodrostat (Isturisa); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pre Eclampsia
Interventions: Sphygmo; Device
Lead sponsor: William Marsh Rice University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obstructive Sleep Apnea of Adult, Preeclampsia, Obstetrical Complications
Interventions: Continuous Positive Airway Pressure, Sleep Advice Control; Device · Other
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more

Conditions: Infant, Newborn, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn, Streptococcal Infections
Interventions: Inhaled Prostaglandin E1; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 7 Days
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 11
States / cities: Birmingham, Alabama • Palo Alto, California • Iowa City, Iowa + 7 more

Conditions: Overweight and Obesity, Insulin Resistance, Diabetes, Gestational, Hypertension in Pregnancy, Pre-Eclampsia
Interventions: DHA Supplements, Placebo Supplements; Dietary Supplement
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Preterm Birth, Preeclampsia
Interventions: Daily aspirin (ASA), Split dose aspirin (ASA); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 16 Years to 55 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pregnancy Induced Hypertension, Preeclampsia and Eclampsia, Gestational Hypertension
Interventions: L-citrulline, Placebo; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Chronic Kidney Disease Mineral and Bone Disorder, Hypertension, Diabetes, Dyslipidemia, Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (Stage 3)
Interventions: Low-dose Colchicine at 0.5mg daily, Usual Care; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 69 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia, Cardiovascular Complication
Interventions: Placebo, Dapagliflozin 10mg Tab; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pre-Eclampsia, Gestational Hypertension, Sleep
Interventions: SNOO, Safe sleep education in the postpartum period; Device · Other
Lead sponsor: Alisse Hauspurg; Other
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Preeclampsia
Interventions: Pravastatin, Placebo; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 3
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania • Galveston, Texas

Conditions: Pre-Eclampsia, Vascular Diseases
Interventions: Omental Biopsy; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Albuminuria, Chronic Kidney Diseases, Diabetes, Hypertension
Interventions: Minuteful - Kidney Urine Analysis Test System; Device
Lead sponsor: Healthy.io Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Garden City, New York

Conditions: Chronic Kidney Disease and Hypertension
Interventions: Baxdrostat/dapagliflozin, Baxdrostat/Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 17
States / cities: Surprise, Arizona • Hollywood, Florida • Port Charlotte, Florida + 14 more

Conditions: Chronic Kidney Disease
Interventions: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 44
States / cities: Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more

Conditions: Diabetes, Kidney Disease, Hypertension
Interventions: losartan 100 mg orally once daily, spironolactone 25 mg orally once daily, placebo once orally once daily; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients

Acute Exercise Effects in Obese Pregnancy

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Using Intradialytic Blood Pressure Slopes to Guide Ultrafiltration

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Response to Anti-hypertensives in Pregnant and Postpartum Patients

Effects of a Whole-food, Plant-based Nutrition Program on BP and Potassium in Subjects With CKD

Study of Nicotinamide in Early Onset Preeclampsia

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Pregnant Women

Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure

DHA Supplements to Improve Insulin Sensitivity in Obese Pregnant Women (The Omega-3 Pregnancy Study)

Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)

Role of L-citrulline in Prevention of Pregnancy Associated Hypertension

Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD

A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

Neonatal Sleep Intervention to Improve Postpartum Hypertension

Pravastatin for Prevention of Preeclampsia

Mechanisms of Pregnancy Vascular Adaptations

Evaluation of the Accuracy and Usability of the Minuteful - Kidney Urine Analysis Test System in the Lay User Hands

A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

Improving Outcomes in Patients With Kidney Disease Due to Diabetes